Key result
Polymorphisms in PDE9A and PDE11A, particularly the PDE11A haplotype GAACC, were significantly associated with the diagnosis of major depressive disorder and remission on antidepressants.
Why the study?
Are polymorphisms in phosphodiesterase genes associated with susceptibility to major depressive disorder and antidepressant treatment response in Mexican Americans?
Population
284 depressed Mexican Americans and 331 matched controls
Comparison
Genotyping SNPs in 21 phosphodiesterase genes vs Matched controls (for MDD susceptibility)
Design
Case-control, double-blind (for the prospective pharmacogenetic study)
Authors
Loading...
PDE2 inhibition may advance HF therapy via cGMP enhancement; extends experimental evidence but leaves clinical translation open.
Case-Control (n=615)
Double-blind
Are polymorphisms in phosphodiesterase genes associated with susceptibility to major depressive disorder and antidepressant treatment response in Mexican Americans?
Polymorphisms in the PDE11A gene are associated with both the diagnosis of major depressive disorder and remission in response to antidepressants, suggesting a role for PDE11A in MDD pathophysiology.
Wong et al. (2006) conducted a case-control in Major depressive disorder (n=615). PDE gene polymorphisms (PDE9A, PDE11A, PDE1A) vs. Matched controls / absence of specific polymorphisms was evaluated on Diagnosis of major depressive disorder and remission on antidepressants. Polymorphisms in PDE9A and PDE11A, particularly the PDE11A haplotype GAACC, were significantly associated with the diagnosis of major depressive disorder and remission on antidepressants.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: